The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic targeting of p53, the most commonly altered gene in human cancer. Cancer Research Catalyst took a deep dive in the latest developments, the status of clinical research, and the next frontiers for the field. The post Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53 appeared first on American Association for Cancer Research (AACR) .
https://www.aacr.org/blog/2026/11/06/cracking-undruggable-cancer-proteins-precision-oncology-meets-p53/